

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 18, 2009**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Interleukin Genetics, Inc.**

**File No. 1-32715 - CF#22870**

---

Interleukin Genetics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 13, 2008.

Based on representations by Interleukin Genetics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through November 13, 2013
Exhibit 10.2	through November 13, 2010
Exhibit 10.3	through November 13, 2010

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Karen J. Garnett  
Assistant Director